Seventeen advanced or metastatic American patients with CDC identified 36 genomic alterations by targeted next-generation sequencing of established rearrangement- and cancer-related genes, e.g., NF2 (29%), SETD2 (24%), SMARCB1 (18%), CDKN2A (12%), PIK3CA (6%), PIK3R2 (6%), FBXW7 (6%), BAP1 (6%), DNMT3A (6%), VHL (6%) and HRAS (6%). This evidence concerns the gene SETD2 and cancer.